AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalyn Pharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$23.33−0.33 (-1.39%)
Close on Oct 19, 2026
- Market cap
- $691.75M
- P/E (TTM)
- –
- Dividend yield
- –
About Avalyn Pharma
Pharmaceutical Preparations, SIC 2834
Avalyn Pharma Inc. is listed on Nasdaq under the ticker AVLN, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Avalyn Pharma Inc.
- Headquarters
- Boston, MA
- Address
- 105 W First St. 02127
- Phone
- (206) 707-0340
- Website
- avalynpharma.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- AVLN
- Exchange
- Nasdaq
- IPO date
- Apr 30, 2026
- Shares outstanding
- 44M, Aug 31, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1540171
- CUSIP
- 05348Y105
- ISIN
- US05348Y1055
- EIN
- 45-2463191
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lyn Baranowski | Chief Executive Officer, Director | – |
| Adam H. Golden | General Counsel | – |
| Melissa Rhodes | Chief Operating Officer | – |
| Douglas R. Carlson | Chief Financial Officer | – |
| Howard Lazarus | Chief Medical Officer | – |
| Robert J. Meyer | Director | – |
| Heather D. Turner | Director | – |
| Jon Congleton | Director | – |
| Kate Haviland | Director | – |
| Erin Lavelle | Director | – |
| Jill Carroll | Director | 1,419,298 |
| David Matthew Friedman | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 30, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 27, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 24, 2017 | Name change | Name changed from Genoa Pharmaceuticals, Inc. to Avalyn Pharma Inc. |